440 related articles for article (PubMed ID: 31982202)
1. Rho-kinase ROCK inhibitors reduce oligomeric tau protein.
Hamano T; Shirafuji N; Yen SH; Yoshida H; Kanaan NM; Hayashi K; Ikawa M; Yamamura O; Fujita Y; Kuriyama M; Nakamoto Y
Neurobiol Aging; 2020 May; 89():41-54. PubMed ID: 31982202
[TBL] [Abstract][Full Text] [Related]
2. Homocysteine Increases Tau Phosphorylation, Truncation and Oligomerization.
Shirafuji N; Hamano T; Yen SH; Kanaan NM; Yoshida H; Hayashi K; Ikawa M; Yamamura O; Kuriyama M; Nakamoto Y
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562600
[TBL] [Abstract][Full Text] [Related]
3. Clioquinol Decreases Levels of Phosphorylated, Truncated, and Oligomerized Tau Protein.
Lin G; Zhu F; Kanaan NM; Asano R; Shirafuji N; Sasaki H; Yamaguchi T; Enomoto S; Endo Y; Ueno A; Ikawa M; Hayashi K; Yamamura O; Yen SH; Nakamoto Y; Hamano T
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769495
[TBL] [Abstract][Full Text] [Related]
4. Pitavastatin decreases tau levels via the inactivation of Rho/ROCK.
Hamano T; Yen SH; Gendron T; Ko LW; Kuriyama M
Neurobiol Aging; 2012 Oct; 33(10):2306-20. PubMed ID: 22133277
[TBL] [Abstract][Full Text] [Related]
5. The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.
Fan SJ; Huang FI; Liou JP; Yang CR
Cell Death Dis; 2018 May; 9(6):655. PubMed ID: 29844403
[TBL] [Abstract][Full Text] [Related]
6. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.
Caccamo A; Magrì A; Medina DX; Wisely EV; López-Aranda MF; Silva AJ; Oddo S
Aging Cell; 2013 Jun; 12(3):370-80. PubMed ID: 23425014
[TBL] [Abstract][Full Text] [Related]
7. Tau therapeutic strategies for the treatment of Alzheimer's disease.
Churcher I
Curr Top Med Chem; 2006; 6(6):579-95. PubMed ID: 16712493
[TBL] [Abstract][Full Text] [Related]
8. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
[TBL] [Abstract][Full Text] [Related]
9. IFN-γ promotes τ phosphorylation without affecting mature tangles.
Li A; Ceballos-Diaz C; DiNunno N; Levites Y; Cruz PE; Lewis J; Golde TE; Chakrabarty P
FASEB J; 2015 Oct; 29(10):4384-98. PubMed ID: 26156074
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease.
Salminen A; Ojala J; Kaarniranta K; Hiltunen M; Soininen H
Prog Neurobiol; 2011 Jan; 93(1):99-110. PubMed ID: 21056617
[TBL] [Abstract][Full Text] [Related]
11. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
Wang JZ; Grundke-Iqbal I; Iqbal K
Eur J Neurosci; 2007 Jan; 25(1):59-68. PubMed ID: 17241267
[TBL] [Abstract][Full Text] [Related]
12. Autophagy and Tau Protein.
Hamano T; Enomoto S; Shirafuji N; Ikawa M; Yamamura O; Yen SH; Nakamoto Y
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299093
[TBL] [Abstract][Full Text] [Related]
13. Role of microtubule-associated protein tau phosphorylation in Alzheimer's disease.
Ma RH; Zhang Y; Hong XY; Zhang JF; Wang JZ; Liu GP
J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):307-312. PubMed ID: 28585125
[TBL] [Abstract][Full Text] [Related]
14. Active c-jun N-terminal kinase induces caspase cleavage of tau and additional phosphorylation by GSK-3beta is required for tau aggregation.
Sahara N; Murayama M; Lee B; Park JM; Lagalwar S; Binder LI; Takashima A
Eur J Neurosci; 2008 Jun; 27(11):2897-906. PubMed ID: 18540881
[TBL] [Abstract][Full Text] [Related]
15. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling.
Kickstein E; Krauss S; Thornhill P; Rutschow D; Zeller R; Sharkey J; Williamson R; Fuchs M; Köhler A; Glossmann H; Schneider R; Sutherland C; Schweiger S
Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21830-5. PubMed ID: 21098287
[TBL] [Abstract][Full Text] [Related]
16. Tau as a therapeutic target for Alzheimer's disease.
Boutajangout A; Sigurdsson EM; Krishnamurthy PK
Curr Alzheimer Res; 2011 Sep; 8(6):666-77. PubMed ID: 21679154
[TBL] [Abstract][Full Text] [Related]
17. Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration.
Gentry EG; Henderson BW; Arrant AE; Gearing M; Feng Y; Riddle NC; Herskowitz JH
J Neurosci; 2016 Jan; 36(4):1316-23. PubMed ID: 26818518
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A.
Martin L; Magnaudeix A; Esclaire F; Yardin C; Terro F
Brain Res; 2009 Feb; 1252():66-75. PubMed ID: 19071093
[TBL] [Abstract][Full Text] [Related]
19. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
20. Tau phosphorylation affects its axonal transport and degradation.
Rodríguez-Martín T; Cuchillo-Ibáñez I; Noble W; Nyenya F; Anderton BH; Hanger DP
Neurobiol Aging; 2013 Sep; 34(9):2146-57. PubMed ID: 23601672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
